Resect Medical, Inc. receives FDA 510(k) clearance to market for InLine Bipolar Coagulator

Washington DC, April 8, 2004. Resect Medical, Inc. receives FDA 510 (k) clearance to market for the InLine^TM Bipolar RF linear coagulator. The InLine system is intended to coagulate tissue during laparoscopic and intraoperative surgical procedures. This is the first of a series of innovative devices the company plans to launch to facilitate surgical resection of solid organs. The InLine system is the only device in the market that creates a variable depth and shape plane of coagulated tissue using bipolar RF energy. This facilitates surgical resection and helps reduce blood loss in patients undergoing solid organ transections. Steven Daniel, Resect Medical´s CEO, stated "we are pleased to announce the introduction of the InLine System to facilitate hemostasis in solid organ resections. InLine is the first device of its kind in the market and is a significant improvement over existing technologies which by their design, can only coagulate small localized areas of tissue with each application. Our initial clinical trials indicate InLine significantly reduces total blood loss and transection times over best available techniques in liver resections. Early results of our ongoing clinical trial will be presented at the 6th World Congress of the International Hepato-Pancreato-Biliary Association in Washington, DC on June 2-5, 2004."